Human Cerebral Organoids - a New Tool for Clinical Neurology Research
Overview
Affiliations
The current understanding of neurological diseases is derived mostly from direct analysis of patients and from animal models of disease. However, most patient studies do not capture the earliest stages of disease development and offer limited opportunities for experimental intervention, so rarely yield complete mechanistic insights. The use of animal models relies on evolutionary conservation of pathways involved in disease and is limited by an inability to recreate human-specific processes. In vitro models that are derived from human pluripotent stem cells cultured in 3D have emerged as a new model system that could bridge the gap between patient studies and animal models. In this Review, we summarize how such organoid models can complement classical approaches to accelerate neurological research. We describe our current understanding of neurodevelopment and how this process differs between humans and other animals, making human-derived models of disease essential. We discuss different methodologies for producing organoids and how organoids can be and have been used to model neurological disorders, including microcephaly, Zika virus infection, Alzheimer disease and other neurodegenerative disorders, and neurodevelopmental diseases, such as Timothy syndrome, Angelman syndrome and tuberous sclerosis. We also discuss the current limitations of organoid models and outline how organoids can be used to revolutionize research into the human brain and neurological diseases.
Martinez-Meza S, Premeaux T, Cirigliano S, Friday C, Michael S, Mediouni S J Neuroinflammation. 2025; 22(1):66.
PMID: 40045391 PMC: 11881274. DOI: 10.1186/s12974-025-03375-w.
Toxicity assessment using neural organoids: innovative approaches and challenges.
Park S, Sun W Toxicol Res. 2025; 41(2):91-103.
PMID: 40013084 PMC: 11850696. DOI: 10.1007/s43188-025-00279-y.
Modeling ALS with Patient-Derived iPSCs: Recent Advances and Future Potentials.
Dawoody Nejad L, Pioro E Brain Sci. 2025; 15(2).
PMID: 40002468 PMC: 11852857. DOI: 10.3390/brainsci15020134.
Aberrant choroid plexus formation drives the development of treatment-related brain toxicity.
Bender T, Schickel E, Schielke C, Debus J, Grosshans D, Durante M Commun Biol. 2025; 8(1):276.
PMID: 39987290 PMC: 11846864. DOI: 10.1038/s42003-025-07736-2.
Galpayage Dona K, Benmassaoud M, Gipson C, McLaughlin J, Ramirez S, Andrews A NeuroImmune Pharm Ther. 2025; 3(2):97-111.
PMID: 39958876 PMC: 11823645. DOI: 10.1515/nipt-2024-0003.